ADMA Biologics
ADMA
179 hedge funds and large institutions have $611M invested in ADMA Biologics in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 62 reducing their positions, and 13 closing their positions.
141% more call options, than puts
Call options by funds: $2.39M | Put options by funds: $994K
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
12% more capital invested
Capital invested by funds: $547M → $611M (+$63.5M)
10% more funds holding
Funds holding: 163 → 179 (+16)
0.03% more ownership
Funds ownership: 74.42% → 74.46% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
6% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 62
Top Buyers
Top Sellers
ADMA Hedge Fund Activity: Q2 2023 in Review
179 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2023, worth a combined $611M — up 12% from $547M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ADMA positions and 13 closed out — a net gain of 16 holders — while 58 added to existing stakes and 62 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $12.7M. The largest seller was State Street, cutting an estimated $9.17M.
- 179 institutional investors held ADMA Biologics (ADMA) as of Q2 2023, up from 163 in Q1 2023.
- Funds reported $611M of ADMA Biologics stock for Q2 2023, up 12% quarter-over-quarter.
- 29 funds opened new ADMA Biologics positions in Q2 2023 and 13 closed out, a net change of +16 holders.
- The largest ADMA Biologics buyer in Q2 2023 was Driehaus Capital Management, an estimated $12.7M added.
- The largest ADMA Biologics seller in Q2 2023 was State Street, an estimated $9.17M sold.
Based on aggregated 13F filings for Q2 2023.